Cytogen returns to Nasdaq compliance

Biopharmaceutical developer Cytogen said that it has been notified by the Nasdaq Stock Market that it has regained compliance with the Nasdaq’s listing standard for minimum bid price. To return to compliance, the Princeton, NJ-based vendor performed a 1-for-10 reverse stock split in late October.

By staff writers
November 12, 2002

Related Reading

Cytogen revenue up in third quarter, November 6, 2002

Cytogen implements reverse stock split, October 28, 2002

Cytogen cuts staff at AxCell unit, September 17, 2002

Cytogen warned by Nasdaq, August 15, 2002

Contrast agents herald new progress in MR lymphography, August 9, 2002

Copyright © 2002

Page 1 of 435
Next Page